Companies in #Obesity

Biopharmaceutical company addressing global unmet medical needs in metabolic diseases, with a focus on drug development and commercialization; HKEX-listed.

Ascletis Pharma is a China-based clinical-stage biopharmaceutical company developing small-molecule and peptide therapeutics for viral diseases, metabolic diseases (including obesity), and oncology. Its lead metabolic candidate ASC36_35 FDC targets GLP-1/GIP agonism.

Kailera Therapeutics is a clinical-stage biopharmaceutical company developing long-acting peptide therapeutics for obesity and metabolic disease, with a lead asset (ribupatide) targeting GLP-1/GIP dual agonism. The company completed a record-setting IPO in early June 2026 and presented positive Chinese Phase 2 data at the American Diabetes Association conference, positioning it as a notable China-originated obesity biotech in the public markets.

Private Northbrook, IL biotech developing melanocortin-system-targeted peptides for obesity, cachexia and related metabolic disorders. Spun out of parent in early 2026.

Kriya Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing AAV-based gene therapies for common chronic diseases of high unmet need, including Type 1 diabetes, obesity, oncology, and rare diseases. Unlike most AAV gene therapy companies that focus on rare diseases with small patient populations, Kriya's strategic differentiation is targeting chronic conditions with much larger patient populations. Kriya operates its own in-house, large-scale GMP manufacturing facilities for gene therapy at its Research Triangle Park (Durham, North Carolina) headquarters — a notable strategic departure from the typical gene therapy CDMO-out-source model. The company was founded in 2019 by Shankar Ramaswamy, M.D. (former senior partner at McKinsey and former CEO of Axovant) and has raised over $600M in venture funding. Kriya was selected in June 2026 for the FDA PreCheck Pilot Program for its Durham, NC manufacturing facility.

MIRA Pharmaceuticals (NASDAQ: MIRA), formerly MIRA1a Therapeutics, is a Miami, Florida-based clinical-stage pharmaceutical company (incorporated 2020, IPO August 2023) developing oral small-molecule therapies for neurologic, neuropsychiatric, and metabolic disorders. Its pipeline includes Ketamir-2, a next-generation oral NMDA receptor modulator with exclusive US, Canadian, and Mexican rights that has completed Phase 1; MIRA-55, an oral non-opioid candidate for chronic inflammatory and neuropathic pain advancing toward IND-enabling studies (7-day toxicology and PK studies completed July 2026); and SKNY-1, a preclinical candidate for obesity and nicotine dependence. On July 27, 2026 the company received a Nasdaq notice of non-compliance with the minimum bid price requirement for continued listing on the Nasdaq Capital Market.

Nitinotes is a medical devices company. See today's news for the latest developments.

Novo Nordisk is a Danish multinational pharmaceutical company that discovers, develops, and markets therapies for diabetes, obesity, rare endocrine disorders, and other chronic diseases. The company is the world's largest insulin producer and a leading developer of GLP-1 receptor agonists for diabetes (Ozempic, Rybelsus) and obesity (Wegovy), with a deep pipeline in cardiometabolic and rare-disease therapeutics.

Sciwind Biosciences is a Chinese clinical-stage biopharmaceutical company developing long-acting peptide therapeutics for metabolic disease, with a lead asset in obesity based on a once-monthly GLP-1/glucagon dual agonist formulation. The company has signed two Western licensing deals for its obesity candidate and is open to additional geographic partnerships as it seeks to expand beyond the Chinese market.

Structure Therapeutics is a clinical-stage biopharmaceutical company developing oral small-molecule therapies for serious diseases, with a lead program (GSBR-1290) in oral GLP-1 receptor agonism for obesity and type 2 diabetes. The company's pipeline targets GPCR-driven metabolic and cardiopulmonary diseases, leveraging structure-based drug design to create differentiated oral alternatives to injectable peptide therapies.